Dizal Pharmaceutical's Zegfrovy has taken the EGFR inhibitor class into new territory after hitting the mark in a phase 3 trial as a first-line treatment for non-small cell lung cancer (NSCLC) with ...

The open-label trial enrolled patients across 16 countries and regions in Europe, Asia, South America, and North America.

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...

The once-daily oral drug improves patients’ lives while maintaining early, durable, and central nervous system responses, ...

The Business Research Company's Non-Small Cell Lung Cancer (NSCLC) Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Non-Small Cell Lung Cancer (NSCLC) Global Market ...

There are many treatment options for lung cancer, but the right one for you will depend on many factors including the type of lung cancer you have. Non-small-cell lung cancer (NSCLC) is the most ...

In Personalized Selection of Immunotherapy Strategies in Metastatic NSCLC and Future Evidence Gaps, our experts delve into ...

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...

Amini: The systemic landscape is constantly changing and is very exciting. It will only become more complicated for our ...

Thanks to recent therapy advances, the lung cancer mortality rate has declined and survival rates have improved. Many factors influence the likelihood of a lung cancer cure or long-term survival, ...

Amini: I believe this is critical for all stages of NSCLC. Whether you are in a small rural practice, large community or ...